News

Exploring the Impact of DS-01® on Gut and Immune Health

Exploring the Impact of DS-01® on Gut and Immune Health

Introduction to DS-01® and its Innovative Formulation

DS-01® stands out as a pioneering broad-spectrum synbiotic, clinically proven to elevate the levels of two important microbial metabolites: Urolithin A and butyrate. These metabolites are vital to overall health, with extensive implications for gut, metabolic, immune, and cellular well-being.

Recent Findings Presented at National Conference

At the recent Digestive Disease Week®, significant clinical data regarding DS-01® was shared, which extends its scientific foundation. The results from an extensive randomized, placebo-controlled clinical trial involving healthy adult participants revealed the remarkable effects of DS-01® on the production of Urolithin A—linked to several health benefits, including aging and metabolism.

Key Outcomes of the Clinical Trials

Among the noteworthy outcomes of the trials was the ability of DS-01® to significantly boost Urolithin A levels, suggesting its role in metabolic health and gut barrier enhancement. Additionally, reductions in C-Reactive Protein (CRP), a marker of inflammation, highlight the synbiotic’s potential role in modulating immune responses.

Details on Clinical Trial Outcomes

The clinical trials comprised multiple phases and concentrated on different health parameters influenced by DS-01®:

Production of Urolithin A

In evaluating the efficacy of DS-01® for increasing Urolithin A synthesis, the study illustrated a remarkable uptick in urinary concentrations of the metabolite. By Day 7 of the trial, participants exhibited elevated urinary Urolithin A levels by almost 100-fold, which remained sustained for a longer duration. Notably, by Day 91, all participants receiving DS-01® transitioned into Urolithin A producers, a stark contrast to a mere 44% in the placebo group.

Impact on Butyrate Levels and Inflammation

The findings also addressed the significant role of butyrate, a short-chain fatty acid essential for colon health and immune function. Participants in the DS-01® group demonstrated increased fecal butyrate levels, compared to no changes in the placebo group. Moreover, there was a marked reduction in CRP levels, linked to themes of systemic inflammation, suggesting that DS-01® might play an instrumental role in enhancing immune health.

Understanding the Biological Relevance

These clinical findings demonstrate more than just microbiome composition changes, affirmatively exhibiting measurable biological outcomes. Zain Kassam, M.D., the Chief Medical Officer at Seed Health, remarked on the study's significance, emphasizing DS-01®’s demonstrated efficacy in fostering critical metabolites that influence gut health, aging, and inflammation.

About Seed Health and its Mission

Seed Health is at the forefront of microbiome science, integrating innovations in probiotics and living medicines to enhance human and environmental health. Focusing on advancing the understanding of the microbiome, the company aims to translate groundbreaking science into effective health outcomes across various demographics and conditions. Offers under the Seed® brand are designed to ensure clinical efficacy in addressing health needs from infancy through aging, while research endeavors include restoring ecosystems through innovative approaches.

Frequently Asked Questions

What is DS-01®?

DS-01® is a groundbreaking synbiotic designed to enhance gut health by increasing the production of beneficial microbial metabolites.

What were the key findings from the recent clinical trials?

The trials demonstrated that DS-01® significantly increases Urolithin A and butyrate levels while reducing inflammation indicated by lower CRP levels.

How does Urolithin A benefit health?

Urolithin A is linked to mitochondrial function, metabolism, and gut health, contributing positively to aging and cellular integrity.

What role does butyrate play in overall health?

Butyrate is crucial for maintaining intestinal health and supporting immune responses, making it an important focus for gut-related health strategies.

What is the mission of Seed Health?

Seed Health aims to pioneer innovations in microbiome science and probiotics to improve health outcomes for both individuals and the environment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LaserAway Opens 241st Clinic, Marks 20-Year Milestone

Updated Category News Views 10

LaserAway's New Chapter in Paramus Out of the glitz of Los Angeles and into the hustle of Paramus, LaserAway's latest clinic isn't just a ribbon-cutting ceremony—it's a milestone in the aesthetic dermatology space. Boasting its 241st location, LaserAway is marking twenty years of relentless expansion without ever closing a single clinic. Now that's a track record that'd...

Continue Reading
TDS Hits Bumps but Keeps Shareholders Happy

Updated Category News Views 48

High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...

Continue Reading
Zylox-Tonbridge's Bold Move with LifeTech Investment

Updated Category News Views 0

An Investment That's Turning Heads Alright, here's a curveball for ya. Zylox-Tonbridge and GL Capital are throwing down a cool HK$1.482 billion into LifeTech Scientific, aiming for a high-stakes play in the vascular and structural heart field. This isn't just peanuts or pocket change; it's a concerted push to carve out a new landscape in China with something akin to a...

Continue Reading
Faith Leaders Reject Dominion-NextEra $67B Merger

Updated Category News Views 122

Voices Raised Against a Corporate Giant Today, outside the drab halls of the Virginia State Corporation Commission (SCC), a group of faith leaders drew a line in the sand against a looming energy giant. The $67 billion move to merge Dominion Energy with NextEra Energy ignited their rallying cry. Phooey to sacrificing community well-being for corporate greed, they shouted....

Continue Reading
Encompass Health Faces Uncertain Future with Sea Pines

Updated Category News Views 94

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Continue Reading
Alpha's Q3 Financials Highlight Operational Hurdles

Updated Category News Views 32

Mixed Bag of Financials Shapes Alpha's Future Alpha Metallurgical Resources, trading under NYSE:AMR, just spilled their Q3 2026 financials, and oh boy, it's a bit of a mixed bag. They reported a net loss of $9.3 million, which ain't exactly a shocker given last quarter's $12.3 million loss. But, hey, they're making some strides with an Adjusted EBITDA of $29.4 million....

Continue Reading
Maxwell M1 Hybrid Unveils Game-Changing Aircraft

Updated Category News Views 72

Welcome to the Future of Amphibious Flight You ever wonder when we'd get past seeing traditional planes stuck at runways? Well, Maxwell Aircraft just fired a hefty shot across the bow with their M1 Hybrid amphibious model. This ain't your run-of-the-mill crate with wings; it's redefining what these birds can do, particularly if you're eyeing remote areas or water-based...

Continue Reading
Andersen's Window Revamp: Addressing Demand Surge

Updated Category News Views 21

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

Continue Reading
CorelDRAW's Flexibility: A Designer's One-Time Buy?

Updated Category News Views 49

CorelDRAW: A Design Powerhouse Without Recurring Bills? Every so often, a software option comes along that piques my interest, and right now, it's CorelDRAW Graphics Suite. Consumer365 has shone a light on this nifty tool for its one-time purchase model—a breath of fresh air in the age of endless subscriptions that seem to drain more than enthusiasm as the months roll...

Continue Reading
Bioactive Research: Converting Science into Guidance

Updated Category News Views 105

Unlocking the Science of Dietary Bioactives Amidst a world swimming in kale smoothies and exotic teas, ILSI U.S. & Canada gathered the sharpest minds to discuss dietary bioactives, an area once shrugged off but now coming into its own. On October 28, 2026, over 250 folks from government, academia, and industry tuned in, looking to understand how these compounds, found in...

Continue Reading

Top 5 Most Recently Viewed Articles

Changshan's Tourism Boom: 22.8% Increase Over Holiday

Updated Category News Views 94

Changshan Grabs Attention This National Day You know, I blinked twice when I saw Changshan's tourist numbers this year. During the 2026 National Day holiday, they managed to snag 503,000 visitors. That's up by a whopping 22.8% from last year. If that doesn't grab your attention, I don't know what will. We're talking record numbers here, folks, and that's the kind of...

Continue Reading
Tenable Recognized for Innovation in Cloud-Native Application Security

Updated Category News Views 181

Tenable's Recognition in Digital Security Landscape Tenable, an industry leader in exposure management, has achieved notable recognition by being named a Major Player in the inaugural IDC MarketScape for Cloud-Native Application Protection Platforms. This acknowledgment reflects the company's commitment to delivering innovative security solutions for contemporary digital...

Continue Reading
Smart Lock Market Growth: Key Trends and Future Outlook

Updated Category News Views 355

Exploring the Smart Lock Market's Dynamic Growth The smart lock market is witnessing an impressive transformation, with the latest analysis revealing a shift from a valuation of US$ 6.33 billion in 2023 to an anticipated US$ 15.42 billion by 2032. This phenomenal growth, driven by a compound annual growth rate (CAGR) of 10.4%, signifies a shift towards more secure and...

Continue Reading
Hamilton Lane Begins Public Offering of Class A Common Stock

Updated Category News Views 190

Hamilton Lane's Strategic Offering of Class A Common Stock Hamilton Lane Incorporated (NASDAQ: HLNE) has announced a public offering of Class A common stock, aiming to issue a total of 1,572,536 shares. This offering will be conducted under an underwritten process, involving Hamilton Lane itself along with a selling stockholder. This strategic step comes amidst shifting...

Continue Reading
Significant Advances by NurExone in Spinal Cord Rehabilitation

Updated Category News Views 111

Exciting Developments in Spinal Cord Injury Treatment NURExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has recently provided incredible insights into the potential of its product ExoPTEN for spinal cord injury treatment. The company's latest preclinical imaging studies reveal significant anatomical changes in the spinal cords of treated animals, suggesting...

Continue Reading